

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



廣州白雲山醫葯集團股份有限公司

**GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.**

*(a joint stock company with limited liability established in the People's Republic of China)*

(H Share Stock Code: 00874)

## **ELECTION OF EMPLOYEE REPRESENTATIVE DIRECTOR OF THE TENTH SESSION OF THE BOARD**

The board of directors (the “**Board**”) of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) announced that, pursuant to the relevant provisions of the Company Law of the People’s Republic of China and the Articles of Association of the Company, the Company recently held the employee representative meeting, at which Mr. Liu Hong (“**Mr. Liu**”) was elected as the employee representative Director of the tenth session of the Board (the “**Employee Representative Director**”). Mr. Liu will form the tenth session of the Board together with the non-employee representative Directors of the tenth session of the Board elected at the Company’s 2025 Annual General Meeting, and the term of office shall expire on the expiry date of the term of office of the tenth session of the Board.

The biographical details of Mr. Liu are set out below:

**Mr. Liu**, aged 37, is a member of the Communist Party of China. He holds a Doctor of Science degree and is a senior engineer in the pharmaceutical industry. He has been recognized as a National Advanced Manufacturing Technology Talent (by the Ministry of Industry and Information Technology, the Ministry of Finance, and the State-owned Assets Supervision and Administration Commission of the State Council), as well as a high-level talent in Guangdong Province and Guangzhou City. He is also an Innovation Talent of the Guangzhou State-owned Assets Supervision and Administration Commission, a Standing Committee Member of the Guangzhou Youth Federation and Deputy Secretary-General of its Pharmaceutical Sector, and a Guangzhou Yangcheng Craftsman. Mr. Liu earned his bachelor’s, master’s, and doctoral degrees, and completed his postdoctoral research from Sun Yat-sen University between 2007 and 2019. From January 2020, he has successively served as Assistant to the Dean, Deputy Dean and Dean of the Pharmaceutical Research Institute of Guangzhou Baiyunshan Guang Hua Pharmaceutical Co., Ltd. (廣州白雲山光華製葯股份有限公司), Chief Engineer of Guangzhou Baiyunshan Tian Xin Pharmaceutical Co., Ltd. (廣州白雲山天心製葯股份有限公司), Deputy Head of the Scientific Research Project Management Department (Postdoctoral Workstation) of Guangzhou Pharmaceutical Holdings Limited (廣州醫葯集團有限公司) (“**GPHL**”), and Deputy Head of the Scientific Research Project Management Department (Postdoctoral Workstation) (“**Scientific Research Project Management Department**”) of the Company. Since December 2025, Mr. Liu has been serving as Head of the Scientific Research Project Management Department of GPHL, Head of the Scientific

Research Project Management Department of the Company, as well as Chairman and General Manager of Guangzhou Baiyunshan XIHE Health Pharmaceutical Co., Ltd (廣州白雲山稀核健康醫藥有限公司), and director of University Biomedical Technology Transfer and Commercialization Center (Guangzhou) Co., Ltd (高校生物醫藥技術轉移轉化中心(廣州)有限公司). Mr. Liu has received numerous awards, including the Gold Award at the National Postdoctoral Innovation and Entrepreneurship Competition and the First Prize in Science and Technology of Guangdong Province, as well as honors such as the National Outstanding Young Engineer Award and the National Outstanding Postdoctoral Fellow in Innovation and Entrepreneurship. Mr. Liu possesses extensive experience in the development of innovation platforms, drug research and development, scientific research project management, and the operational management of pharmaceutical companies.

The Company will enter into a director's service contract with Mr. Liu. Mr. Liu will not receive any remuneration in respect of his appointment as the Employee Representative Director of the Company, save for the corresponding remuneration for his other positions held within the Company.

Save as disclosed above, as of the date of this announcement, Mr. Liu: (i) has no relationship with any Director, senior management, substantial shareholder, or controlling shareholder of the Company; (ii) has not held any directorship in any listed public company the securities of which are listed on any securities market in Hong Kong or overseas in the past three years, nor any other major appointments or professional qualifications; (iii) does not hold any other position in the Company or any of its subsidiaries; and (iv) does not have, nor is he deemed to have, any interests in the shares of the Company as defined under Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, there are no other matters in relation to the election of Mr. Liu as the Employee Representative Director that shall be brought to the attention of the shareholders of the Company and the Stock Exchange of Hong Kong Limited, nor are there any other matters which would require disclosure under rule 13.51(2) of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

The Board of  
**Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited**

Guangzhou, the PRC, 15 May 2026

*As at the date of this announcement, the Board comprises Mr. Li Xiaojun, Mr. Chen Jiehui, Mr. Cheng Hongjin, Mr. Tang Heping and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.*